报价延迟最少15分钟:2026/04/21 22:31 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.8 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.38/-0.44
|
|
企业价值
258.21M
|
| 资产负债 |
|
每股账面净值
0.54
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
7.67M
|
|
每股收益
0.34
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies. |
